Project Grant R25CA278725
Award Date
9/4/24
Completion Date
8/31/29
Dollars Obligated
$315K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This $132,015 Project Grant award was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to The Ohio State University. The funding will support efforts to improve enrollment in clinical trials for gynecologic cancers, especially among underrepresented populations. Key activities include: Developing a comprehensive system at The Ohio State University Comprehensive Cancer Center to streamline molecular matching and identification of patients for...
The National Cancer Institute (NCI) awarded a 5-year, $162,160 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Ohio State University to improve the assessment of patient-reported outcomes (PROs) among Black/African-American cancer patients. The research will involve qualitative interviews with Black cancer patients and their providers to understand barriers and facilitators to completing PROs and social determinants of health (SDH) measures. This knowledge will inform the...
The federal Project Grant award of $1,574,999.00 was provided by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to The Ohio State University for the project "SLIT2 AS A NOVEL APPROACH FOR TARGETING METASTATIC BREAST CANCER". The award, with a performance period from June 15, 2025 to June 14, 2028, supports advanced biomedical research focused on transforming healthcare for military service members and the broader...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University totals $1,791,693 over a 5-year period from August 1, 2024 to July 31, 2029. The objectives of this research project are to investigate how blocking the CD200R immune checkpoint can enhance cancer immunotherapy by improving the recruitment and function of tumor-infiltrating immune cells, as well as inhibiting tumor angiogenesis. The research will evaluate the roles...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) is providing $111,502.00 to The Ohio State University to support research on the biochemical properties and implications of NRAS mutant-specific BRAF interactions in melanoma. The goal is to elucidate the structural determinants and signaling mechanisms that drive the selectivity of specific NRAS mutations in melanoma development, which could help identify novel therapeutic approaches....
The federal Project Grant award in the amount of $826,875.00 was granted by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant is titled "NOVEL ROLES OF SLIT2 IN ENHANCING ANTITUMOR IMMUNITY IN SMALL CELL LUNG CANCER" and supports research conducted by The Ohio State University from June 15, 2025 to June 14, 2028. The research aims to investigate innovative approaches to enhancing antitumor immunity for the treatment of...
The federal Project Grant award of $1,317,976.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding research at The Ohio State University to target the RAL G proteins in order to develop new treatments for triple-negative breast cancer. The grant period runs from July 1, 2025 to June 30, 2028. The Ohio State University has extensive experience delivering advanced biomedical research for federal agencies and...
The National Cancer Institute (NCI) awarded a $178,541 Project Grant to Oregon Health & Science University (OHSU) under the Cancer Research Manpower (CFDA 93.398) program. The 5-year grant, starting on January 15, 2025, will fund the "Experimental Therapeutics in Cancer (ETC) Training Program" to train a total of 9 PhD and MD postdoctoral fellows in oncological drug development and translational cancer research. The ETC program will leverage OHSU's expertise as an NCI-designated...
This Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to enhance the efficacy of antibody-based therapies for chronic lymphocytic leukemia (CLL). The $621,637 award to The Ohio State University, spanning Sept 2024 to Aug 2029, will investigate mechanisms by which activating the NOD2 receptor can enhance monocyte and natural killer cell function to improve antibody-mediated depletion of CLL cells. The...
The National Cancer Institute (NCI) awarded Emory University a $312,737 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program. The "Georgia Science Education Initiative NCI YES (GA-YES)" program aims to recruit and train high school students underrepresented in STEM careers, with a focus on rural and lower socioeconomic status students, in cancer research and disparities. Key program components include: 1) a summer mentored cancer research training...